These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1100342)

  • 41. [Acute psychotic status after sudden interruption of treatment of Parkinsonism with levodopa].
    Ledić P; Sepcić J; Antoncić N
    Neurologija; 1977; 25(1-2):95-7. PubMed ID: 616879
    [No Abstract]   [Full Text] [Related]  

  • 42. [Levodopa and Parkinsonism. A double-blind study].
    Pakkenberg H; Dupont E; Garde B; Hansen E; Melsen S; Vestberg F
    Ugeskr Laeger; 1971 Nov; 133(46):2275-9. PubMed ID: 4944650
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 44. Adverse clinical side effects of levodopa therapy.
    Barbeau A; Mars H; Gillo-Joffroy L
    Contemp Neurol Ser; 1971; 8():203-37. PubMed ID: 5293414
    [No Abstract]   [Full Text] [Related]  

  • 45. Response of tardive and L-dopa-induced dyskinesias to antidepressants.
    el-Awar M; Freedman M; Seeman P; Goldenberg L; Little J; Solomon P
    Can J Neurol Sci; 1987 Nov; 14(4):629-31. PubMed ID: 3690436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
    Steiger MJ; Quinn NP; Marsden CD
    Mov Disord; 1991; 6(1):91-2. PubMed ID: 2005934
    [No Abstract]   [Full Text] [Related]  

  • 47. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 48. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
    Nygaard TG
    Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
    Chouinard G; Annable L; Mercier P; Turnier L
    Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
    [No Abstract]   [Full Text] [Related]  

  • 52. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
    Gilligan B; Hancock R
    Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 54. [Acute pharmacotoxic psychoses in patients with chronic cerebral disorders].
    Danielczyk W
    Wien Med Wochenschr Suppl; 1979; 55():1-15. PubMed ID: 34935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 56. [Indications and results of monoamine treatment in parkinsonian syndromes].
    Boudin G; Pépin B; Guillard A; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1972 Jul; 127(1):79-97. PubMed ID: 4520464
    [No Abstract]   [Full Text] [Related]  

  • 57. [Side effects in the treatment with L-dopa].
    Vladyka V
    Cesk Neurol Neurochir; 1975 Jan; 38(1):34-40. PubMed ID: 1111993
    [No Abstract]   [Full Text] [Related]  

  • 58. The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients.
    Wilson JA; Smith RG
    Age Ageing; 1989 Jan; 18(1):11-6. PubMed ID: 2711918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroleptics and the elderly.
    Peabody CA; Warner MD; Whiteford HA; Hollister LE
    J Am Geriatr Soc; 1987 Mar; 35(3):233-8. PubMed ID: 2880887
    [No Abstract]   [Full Text] [Related]  

  • 60. [Side-effects in nitrothiamidazole (Ambilihar) therapy].
    Mohr W; Roth C
    Z Tropenmed Parasitol; 1968 Sep; 19(3):263-4. PubMed ID: 5720327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.